Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC

This observational study in China examines whether adding a procedure called HAIC (hepatic arterial infusion chemotherapy — delivering chemotherapy directly into the liver's blood supply) to standard immunotherapy and anti-angiogenic (blood vessel-blocking) drugs improves outcomes for people with advanced liver cancer (hepatocellular carcinoma, or HCC). **You may be eligible if:** - You have confirmed liver cancer (HCC) by imaging, biopsy, or lab tests - Your cancer is at an advanced stage (BCLC stage B or C) - You have not received prior systemic (whole-body) treatments for HCC - You are receiving both immunotherapy (PD-1/PD-L1 inhibitors) and anti-angiogenic drugs, with or without HAIC **You may NOT be eligible if:** - You have already received systemic treatment for liver cancer - You are at an early stage eligible for curative treatment - You have serious liver failure or other conditions making you ineligible Note: This is an observational study — researchers analyze outcomes from patients already receiving treatment, without assigning experimental therapies. Talk to your doctor to see if this trial is right for you.